India's Hepatitis C Virus Drug Market Will Grow to More than $171 Million by 2012

Wednesday, October 8, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

WALTHAM, Mass., Oct. 7 Decision Resources, one of theworld's leading research and advisory firms focusing on pharmaceutical andhealthcare issues, forecasts that the Indian hepatitis C virus drug marketwill grow from $21.6 million in 2007 to more than $171 million by 2012.According to the new Emerging Markets report entitled Hepatitis C Virus inIndia, this growth will be fueled by increasing diagnosis and drug treatmentrates.

"Growth of India's hepatitis C drug market will be a direct result ofincreasing diagnosis and treatment rates in urban areas," said John Lebbos,M.D., Vice President of Infectious Diseases at Decision Resources. "However,the majority of the hepatitis C virus prevalent population resides in ruralareas, where diagnosis and treatment of hepatitis C are inadequate. Althoughwe anticipate some improvement by 2012, this population will likely remain anuntapped opportunity for growth."

Additionally, the report finds that the number of prevalent cases ofchronic hepatitis C virus in India (8.5 million in 2007) is greater than thatof the United States, France, Germany, Italy, Spain, United Kingdom and Japancombined. However, both diagnosis rates and drug treatment rates in India areextremely low, resulting in a virtually untapped antiviral market for thedisease.

"Because the general public in India is poorly informed about thehepatitis C virus, few people who unknowingly have the disease understand therisk factors enough to realize they should be tested for the disease. Thosewho do get tested often cannot afford treatment," added Dr. Lebbos.

The report also finds that familiarity with drug treatment options forhepatitis C varies by region and clinical experience. Clinicians surveyed inDelhi, Jaipur and Lucknow are generally less familiar with hepatitis Ctherapeutics than are their colleagues in Mumbai, Bangalore and Chennai. Notsurprisingly, gastroenterologists are typically more familiar than generalpractitioners with the appropriate therapies for the disease.


The Ultimate Analysis of Pharmaceutical Markets in China and India

Decision Resources is the FIRST and ONLY company to offer a syndicatedreport series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in thepharmaceutical market for a disease based on population demographics, economicdevelopment, disease epidemiology and changing physicians' practices.

About Decision Resources

Decision Resources ( is a world leader in marketresearch publications, advisory services and consulting designed to helpclients shape strategy, allocate resources and master their chosen markets.Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offersbest-in-class, high-value information and insights on important sectors of thehealthcare industry. Clients rely on this analysis and data to make informeddecisions. Please visit Decision Resources, Inc. .

All company, brand or product names contained in this document may betrademarks or registered trademarks of their respective holders.For more information, contact: Natalia Morales Elizabeth Marshall Decision Resources Decision Resources, Inc. 781-296-2691 781-296-2563

SOURCE Decision Resources

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store